World Health Organization. Global Tuberculosis Report 2018.Executive Summary. Geneva. Switzerland. 2018
Rajeswari R, Balasubramanian R, Muniyandi M, et al.Socio-economic impact of tuberculosis on patients andfamily in India. Int J Tuberc Lung Dis 1919;3(10):869-77.
Zenner D, Loutet MG, Harris R, et al. Evaluation of 17 yearsof LTBI screening in North West England: A retrospectivecohort study of reactivation. Eur Respir J 2017;50:1602505.
Houben RMGJ, Dodd PJ, The Global Burden of LatentTuberculosis Infection: A Re- estimation using mathematicalmodeling. PloS Med 2016;13(10):e1002152.
Rissel NL, Belcher BW, Bushyhead JB et al. The Accuracyof Tuberculin Skin Test: Self-Assessment by Adult Outpatients.Public Health Rep. July- August 1985; 100(4): 439-445
Lee E, Holzman RS. Evolution and Current Use of theTuberculin Test. Clin Infect Dis 2002;34:365-70
Yi L, Sasaki Y, Nagai H, et al. Evaluation of QuantiFERON-TBGold Plus for detection of Mycobacterium tuberculosisinfection in Japan. Sci Rep 2016;6:30617.
Azghay M, Bouchaud O, Mechai F et al. Utility of QuantiREFON-TB Gold In-Tube assay in adult, pulmonary andextrapulmonary, active tuberculosis diagnosis. Int J Infect Dis2016;44:25-30.
Kim HW, Kim JS. Treatment of Latent Tuberculosis Infectionand Its Clinical Efficacy. Tuberc Respi Dis (Seoul)2018;81(1):6-12.
Luetkemeyer AF, Charlebois ED, Flores LL et al. Comparisonof an interferon-y Release Assay with Tuberculin Skin Testingin HIV- infected individuals. AM J Respir Crit Care Med2007;175:737-42.
Saenghirunvattana S. Useful of Quantiferon G in managingsolitary pulmonary nodule of less than 3cm. Eur Respir J2011;38:2659.
Andrews JR, Hatherill M, Mahomed H, et al. The dynamicsof QuantiFERON-TB Gold IN-TUBE Conversion andReversion in a Cohort of South African Adolescents. Am JRespair Crit Care Med 2015;191(5):584-91.
Johnson JL MD, Geldenhuys H, Thiel B et al. Effects ofIsoniazid Therapy for Latent TB Infection on QauntiFERON-TBGold In-Tube responses in adults with positive TuberculinSkin Test Results in a High Incidence Area. Chest2014;145(3):612-7.
World Health Organization. Implementing the WHO Stop TBStrategy: A Handbook for National Tuberculosis ControlPrograms 2008. Geneva. Switzerland.
Saenghirunvattana S. Effect of Isoniazid prophylaxis onincidence of active tuberculosis among Thai HIV-infectedindividuals, J Med Assoc Thai 1996:79(5):285-7.
Centers for Disease Prevention. Severe Isoniazid AssociatedLiver Injuries among persons being treated for LatentTuberculosis Infection-United States-2004-2008. MMWRMorb Mortal Rep 2010;59(08);224-9.
Komiya K, Ariga H, Kurashima A, et al. Reversion rates ofQuantiFERON-TB Gold are related to pretreatmentIFN-gamma levels, J Infect 2011;63(1):48-53
Pettruccioli E, Vanini V, Chiacchio T et al. Analyticalevaluation of Quantiferon-Plus and Quantiferon-Gold In-Tubeassays in subjects with or without tuberculosis. Tuberculosis2017;106:38-43.
